PMID- 20517472
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20110714
LR  - 20240317
IS  - 1177-889X (Electronic)
IS  - 1177-889X (Linking)
VI  - 4
DP  - 2010 May 13
TI  - One-pill once-a-day HAART: a simplification strategy that improves adherence and 
      quality of life of HIV-infected subjects.
PG  - 115-25
AB  - OBJECTIVE: The aim of the ADONE (ADherence to ONE pill) study was to verify the 
      effect of a reduced number of pills on adherence and quality of life (QoL) in 
      HIV-infected patients on highly active antiretroviral therapy (HAART). DESIGN: 
      Prospective, multicenter, study. METHODS: Patients chronically treated with 
      emtricitabine (FTC) + tenofovir (TDF) + efavirenz (EFV) or lamivudine (3TC) +TDF 
      +EFV and with a HIV-RNA < 50 copies/mL were switched to the single-pill 
      fixed-dose regimen (FDR) of FTC +TDF +EFV. Data were collected with SF-36 using 
      visual analog scales. Results of the final (6 months) primary as-treated analysis 
      are reported. RESULTS: 212 patients (77.4% males) of mean age 45.8 years were 
      enrolled; 202 completed the study. One month post switch to FDR the adherence 
      rate increased significantly to 96.1% from a baseline value of 93.8% (P < 0.01). 
      The increase was steadily maintained throughout the study (96.2% at 6 months). 
      QoL improved over time from 68.8% to 72.7% (P = 0.042) as well, and was 
      significantly associated with the perception of health status, presence of 
      adverse events (AEs) and number of reported AEs (P < 0.0001). QoL significantly 
      influenced adherence (P < 0.0001). During FDR use the mean CD4 count increased 
      from 556 to 605 cells/muL (P < 0.0001). At the end of follow-up 98% of patients 
      maintained HIV-RNA level < 50 copies/mL and 100% <400 copies/mL. Four patients 
      stopped therapy because they were lost to follow-up and 6 because of AEs 
      (insomnia/nervousness 4, allergy 1, difficulties swallowing pills 1). CONCLUSION: 
      By substituting a one-pill once-a-day HAART, we observed an improvement of both 
      adherence and QoL while maintaining high virologic and immunologic efficacy. 
      HAART simplicity is an added value that favors adherence and may improve 
      long-term success.
FAU - Airoldi, Monica
AU  - Airoldi M
AD  - Division of Infectious Diseases, Ospedali Riuniti, Bergamo;
FAU - Zaccarelli, Mauro
AU  - Zaccarelli M
FAU - Bisi, Luca
AU  - Bisi L
FAU - Bini, Teresa
AU  - Bini T
FAU - Antinori, Andrea
AU  - Antinori A
FAU - Mussini, Cristina
AU  - Mussini C
FAU - Bai, Francesca
AU  - Bai F
FAU - Orofino, Giancarlo
AU  - Orofino G
FAU - Sighinolfi, Laura
AU  - Sighinolfi L
FAU - Gori, Andrea
AU  - Gori A
FAU - Suter, Fredy
AU  - Suter F
FAU - Maggiolo, Franco
AU  - Maggiolo F
LA  - eng
PT  - Journal Article
DEP - 20100513
PL  - New Zealand
TA  - Patient Prefer Adherence
JT  - Patient preference and adherence
JID - 101475748
PMC - PMC2875721
OTO - NOTNLM
OT  - EFV/FTC/TDF
OT  - QoL
OT  - adherence
OT  - once-daily antiretroviral regimen
OT  - patient preferences
OT  - single-pill regimen
EDAT- 2010/06/03 06:00
MHDA- 2010/06/03 06:01
PMCR- 2010/05/13
CRDT- 2010/06/03 06:00
PHST- 2010/05/03 00:00 [received]
PHST- 2010/06/03 06:00 [entrez]
PHST- 2010/06/03 06:00 [pubmed]
PHST- 2010/06/03 06:01 [medline]
PHST- 2010/05/13 00:00 [pmc-release]
AID - ppa-4-115 [pii]
AID - 10.2147/ppa.s10330 [doi]
PST - epublish
SO  - Patient Prefer Adherence. 2010 May 13;4:115-25. doi: 10.2147/ppa.s10330.